# Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma

> **NCT01356173** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma, Solid Tumor

## Interventions

- **DRUG:** GDC-0349

## Key facts

- **NCT ID:** NCT01356173
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01356173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01356173, "Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01356173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*